Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.

Marcello MocciaRaffaele PalladinoRoberta LanzilloAntonio CarotenutoCinzia Valeria RussoMaria TriassiVincenzo Brescia Morra

Published in: PloS one (2017)

Higher healthcare costs for treating MS have been associated with a milder disease evolution after 10 years, with possible reduction of long-term non-medical direct and indirect costs.

Keyphrases

multiple sclerosis
healthcare
white matter
mass spectrometry
rheumatoid arthritis
disease activity